TGM2 and juvenile Huntington disease: In particular, treatment with cystamine, a TGase inhibitor (33), or ablation of TGase2 (34) delays the onset of neurological symptoms and improves the life expectancy of Huntington’s disease model mice, suggesting that aberrant activation of TGase2 may be involved in the formation of insoluble aggregates in neurons through protein modification during ageing.